Patents by Inventor Mark Karbarz

Mark Karbarz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
    Patent number: 12115154
    Abstract: The present disclosure relates to novel compounds capable of binding to PCSK9, thereby modulating PCSK9 biological activity. Also provided are compositions comprising these compounds, methods of preparing the compounds, and methods for use of the compounds in the treatment of PCSK9-related conditions and diseases.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: October 15, 2024
    Assignee: SRX Cardio, LLC
    Inventors: Simeon Bowers, Mark Karbarz, Jiang Zhu, Thomas E. Barta, Jonathan William Bourne, Anjali Pandey
  • PREPARATION OF FACTOR XA DERIVATIVES
    Publication number: 20240076642
    Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
    Type: Application
    Filed: November 8, 2023
    Publication date: March 7, 2024
    Inventors: Mark Karbarz, Pamela B. Conley, Genmin Lu
  • Preparation of factor Xa derivatives
    Patent number: 11845966
    Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
    Type: Grant
    Filed: March 9, 2021
    Date of Patent: December 19, 2023
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Mark Karbarz, Pamela B. Conley, Genmin Lu
  • COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)
    Publication number: 20220267269
    Abstract: The present disclosure relates to novel compounds capable of binding to PCSK9, thereby modulating PCSK9 biological activity. Also provided are compositions comprising these compounds, methods of preparing the compounds, and methods for use of the compounds in the treatment of PCSK9-related conditions and diseases.
    Type: Application
    Filed: June 12, 2020
    Publication date: August 25, 2022
    Inventors: Simeon Bowers, Mark Karbarz, Jiang Zhu, Thomas E. Barta, Jonathan William Bourne, Anjali Pandey
  • COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9)
    Publication number: 20220193058
    Abstract: The present disclosure relates to novel compounds capable of binding to PCSK9, thereby modulating PCSK9 biological activity. Also provided are compositions comprising these compounds, methods of preparing the compounds, and methods for use of the compounds in the treatment of PCSK9-related conditions and diseases.
    Type: Application
    Filed: December 16, 2020
    Publication date: June 23, 2022
    Inventors: Simeon Bowers, Mark Karbarz, Jiang Zhu, Thomas E. Barta, Jonathan William Bourne, Anjali Pandey
  • INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES
    Publication number: 20210379163
    Abstract: The present disclosure relates to compositions and methods for the treatment of bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand (vWF) disease, and factor XII deficiency, by reducing the circulating concentration of tissue factor pathway inhibitor (TFPI), with a factor Xa derivative.
    Type: Application
    Filed: February 16, 2021
    Publication date: December 9, 2021
    Inventors: Genmin Lu, Uma Sinha, Mark Karbarz, Anjali Pandey, Pamela B. Conley
  • PREPARATION OF FACTOR XA DERIVATIVES
    Publication number: 20210348149
    Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
    Type: Application
    Filed: March 9, 2021
    Publication date: November 11, 2021
    Inventors: Mark Karbarz, Pamela B. Conley, Genmin Lu
  • Preparation of factor Xa derivatives
    Patent number: 10954504
    Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: March 23, 2021
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Mark Karbarz, Pamela B. Conley, Genmin Lu
  • PREPARATION OF FACTOR XA DERIVATIVES
    Publication number: 20200208131
    Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
    Type: Application
    Filed: January 10, 2020
    Publication date: July 2, 2020
    Inventors: Mark Karbarz, Pamela B. Conley, Genmin Lu
  • Preparation of factor Xa derivatives
    Patent number: 10604748
    Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: March 31, 2020
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Mark Karbarz, Pamela B. Conley, Genmin Lu
  • INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES
    Publication number: 20180333469
    Abstract: The present disclosure relates to compositions and methods for the treatment of bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand (vWF) disease, and factor XII deficiency, by reducing the circulating concentration of tissue factor pathway inhibitor (TFPI), with a factor Xa derivative.
    Type: Application
    Filed: March 12, 2018
    Publication date: November 22, 2018
    Inventors: Genmin Lu, Uma Sinha, Mark Karbarz, Anjali Pandey, Pamela B. Conley
  • PREPARATION OF FACTOR XA DERIVATIVES
    Publication number: 20170369862
    Abstract: The present disclosure provides methods for manufacturing a fXa derivative protein at large scale leading to high yield of highly pure protein product. The method may include adding a detergent to a sample that contains a polynucleotide construct encoding the protein and purifying the protein through a soybean trypsin inhibitor (STI)-based affinity chromatograph, an ion exchange and mixed mode chromatograph and a hydrophobic interaction.
    Type: Application
    Filed: June 19, 2017
    Publication date: December 28, 2017
    Applicant: Portola Pharmaceuticals, Inc.
    Inventors: Mark Karbarz, Pamela B. Conley, Genmin Lu
  • INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES
    Publication number: 20150352194
    Abstract: The present disclosure relates to compositions and methods for the treatment of bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand (vWF) disease, and factor XII deficiency, by reducing the circulating concentration of tissue factor pathway inhibitor (TFPI), with a factor Xa derivative.
    Type: Application
    Filed: March 13, 2013
    Publication date: December 10, 2015
    Inventors: Genmin Lu, Uma Sinha, Mark Karbarz, Anjali Pandey, Pamela B. Conley